Pfizer Just Locked Next Growth Path: What Investors Should Know
Pfizer has reset its growth trajectory with big bets on Seagen and a future GLP-1 drug. This analysis breaks down wha...
Coping with unexpected personal finance challenges involves rapid assessment, prioritizing essentials, and building a short-term recovery plan you can follow.
15,854 articlesPfizer has reset its growth trajectory with big bets on Seagen and a future GLP-1 drug. This analysis breaks down wha...
Bond traders are diverging from policy cues as fed’s rate lever breaking unsettles the traditional link between centr...
A leading venture capital investor argues that Elon Musk has largely solved the physics hurdles for SpaceX’s Starlink...
Deribit and SignalPlus unveil The Island, a 35-day crypto trading contest with a prize pool of up to $600,000 USDC. T...
New-home sales in December 2025 rose versus a year ago, but prices fell as concessions increased. The release was del...
A thoughtful look at Xeris Biopharma's Q4 2025 earnings, the company’s pipeline milestones, and what xeris biopharma ...
KeyBanc maintains an overweight stance on AeroVironment after Q3 results, signaling the stock could benefit from esca...
A New Mexico jury awarded Meta $375 million in a landmark ruling over child-safety claims, challenging broad protecti...
Rivian has captured imaginations—and capital. But the next 12 months will test its ability to scale, control costs, a...
A major hedge fund shift has sparked fresh questions about Privia Health. This article dives into what the move signa...
Rivian's R2 rollout marks a new chapter for the EV maker. This guide breaks down whether the stock deserves a place i...
AMD tracks a rapid data-center rebound with 57% YoY growth, challenging Nvidia as hyperscalers back MI450. Investors ...